Acute exacerbation of chronic obstructive pulmonary disease Chronic obstructive pulmonary disease
Conditions
Interventions
Patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease during the intervention period who received nebulized revefenacin in addition to standard-of-care therapy through
Treatment,Treatment
Revenafacin,Control
Sponsors
Navamindradhiraj University
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 40 years or older, 2. Patients hospitalized with a primary diagnosis of acute exacerbation of chronic obstructive pulmonary disease, 3. Patients who received inpatient treatment according to institutional standard-of-care protocols for acute exacerbation of chronic obstructive pulmonary disease, 4. Availability of complete medical records sufficient for assessment of study outcomes.
Exclusion criteria
Exclusion criteria: 1. A history suggestive of asthma or asthma-chronic obstructive pulmonary disease overlap, 2. Chest radiographic findings consistent with alternative diagnoses, including pulmonary edema, bacterial pneumonia, pneumothorax, or other conditions explaining acute respiratory deterioration, 3. Hospitalization for more than 48 hours prior to the diagnosis of acute exacerbation of chronic obstructive pulmonary disease, 4. A diagnosis of unstable cardiovascular disease within three months prior to enrollment, including myocardial infarction, atrial fibrillation with rapid ventricular response, or ventricular tachycardia, 5. A known history of hypersensitivity or severe adverse reactions to long-acting muscarinic antagonists, including revefenacin, anticholinergic agents, or any excipients contained in the nebulized formulation, 6. Advanced chronic kidney disease with an estimated glomerular filtration rate of 15 mL/min/1.73 m2 or less, or receipt of renal replacement therapy, 7. Chronic liver disease with a Child-Pugh score of 7 or higher, 8. Pregnancy or breastfeeding, 9. Prior participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of hospital stay From hospital admission to discharge during the index hospitalization. the number of days from hospital admission to hospital discharge, obtained from electronic medical records. | — |
Secondary
| Measure | Time frame |
|---|---|
| 30-day treatment failure Within 30 days after hospital discharge. Treatment failure was defined as a composite outcome of hospital readmission, re-intubation, or death within 30 days after hospital discharge, assessed using medical records.,Frequency of short-acting bronchodilator use During the index hospitalization. Frequency of short-acting bronchodilator administration during hospitalization, recorded from medication administration records.,Duration of intubation During the index hospitalization Duration of invasive mechanical ventilation, defined as the total number of days of endotracheal intubation during hospitalization, obtained from clinical records.,reatment-related adverse events During the index hospitalization. Treatment-related adverse events were identified and recorded based on physician documentation and nursing records during hospitalization. | — |
Countries
Thailand
Contacts
Public ContactNalin Sampoonachot
Faculty of Medicine Vajira Hospital, Navamindradhiraj University
Outcome results
None listed